Although whether the feasibility and safety of intratumoral injection of OBP-702 in CRC patients remains to be elucidated, rectal cancers with KRAS/BRAF mutations may be potent candidate for treating with OBP-301 and OBP-702. Here, KRAS is linked to rectal cancer.